Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Novalis LifeSciences LLC is an investment and advisory firm focused on the life sciences industry. Founded in 2017 by Marijn E. Dekkers, the firm is headquartered in the United States. Novalis specializes in providing direct investments through its venture capital and private equity arms, as well as offering business advisory services through Novalis Advisory. The firm is committed to supporting companies at various stages of development within the life sciences sector.
As of now, Novalis manages $500 million in assets across three funds, which allows it to provide substantial venture capital and private equity funding to promising companies. The firm has built a diverse portfolio of 17 companies, showcasing its commitment to the growth of the life sciences sector. Notable milestones include successful acquisitions of portfolio companies, highlighting the firm's ability to identify and nurture high-potential investments.
Novalis LifeSciences invests primarily in the life science tools, diagnostics, and biopharma therapeutics sectors. The firm targets companies at various stages of development, including pre-seed, seed, seed+, Series A, Series B, and Series C. This broad stage focus allows Novalis to engage with startups at critical points in their growth trajectories.
With a strong emphasis on growth equity, Novalis seeks to provide substantial funding to innovative companies that demonstrate potential for significant impact in the life sciences field. The firm looks for founders who possess deep industry knowledge and a clear vision for their companies. Novalis prefers to structure deals that allow for active involvement in the growth of its portfolio companies, leveraging its extensive industry expertise and network.
Novalis LifeSciences has built a notable portfolio of 17 companies, each contributing to advancements in the life sciences sector. Key portfolio companies include:
This diverse portfolio reflects Novalis's commitment to advancing innovative solutions in healthcare and biotechnology.
Marijn E. Dekkers: Founder of Novalis LifeSciences, Marijn has extensive experience in the life sciences sector, having previously held leadership positions in various biotech companies. His expertise lies in strategic investments and operational management within the industry.
To pitch to Novalis LifeSciences, startups should visit their website at novalislifesciences.com. The pitch deck should include a comprehensive overview of the business, market analysis, and financial projections. While specific response times are not mentioned, it is advisable to follow up after submitting a pitch to ensure it has been received.
In August 2024, Novalis LifeSciences celebrated the acquisition of its portfolio company, Cerevel Therapeutics, by AbbVie, marking a significant exit for the firm. Additionally, Decipher Biosciences was acquired by Veracyte in March 2021, further showcasing Novalis's successful investment strategy.
Recent public listings include Quanterix in December 2017 and Ginkgo Bioworks in September 2021, highlighting the firm's ability to identify and support companies that achieve significant milestones in their growth.
What are Novalis LifeSciences' investment criteria?
Novalis LifeSciences invests in companies within the life sciences sector, focusing on biopharma, diagnostics, and life science tools. They target various stages, including pre-seed, seed, Series A, and beyond.
How can startups apply or pitch to Novalis LifeSciences?
Startups can pitch to Novalis LifeSciences through their website at novalislifesciences.com. It is advisable to include a detailed business plan and financial projections in the pitch deck.
What makes Novalis LifeSciences different from other investors?
Novalis LifeSciences combines venture capital with advisory services, providing not only funding but also strategic guidance and industry expertise to its portfolio companies.
What is the geographic scope of Novalis LifeSciences' investments?
Novalis LifeSciences primarily invests in companies based in the United States, focusing on the life sciences sector.
What is the typical check size for investments?
While specific check sizes are not disclosed, Novalis LifeSciences manages $500 million across its funds, indicating a capacity for substantial investments in promising companies.
What kind of post-investment involvement does Novalis LifeSciences have?
Novalis LifeSciences actively engages with its portfolio companies, providing strategic guidance and leveraging its network to support growth and navigate challenges.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.